- Regulation
- Approvals
Novartis gets EC nod for Cosentyx drug in paediatric psoriasis
Novartis has secured approval from the European Commission (EC) for its Cosentyx (secukinumab) to treat moderate-to-severe plaque psoriasis in children and adolescents aged between six and 18 years
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
大家都用什么翻墙Sign up to our free email to get all the latest PBR
news.




